The challenge of defining mesenchymal stromal cell potency assays and their potential use as release criteria

Affiliations

¹ Department of Hematology and Medical Oncology, Winship Cancer Institute, and Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA. Electronic address: jgalipe@emory.edu.
² Section of Hematology, Stem Cell Research Laboratory and Cell Factory, Department of Medicine, University of Verona, Policlinico G.B. Rossi, P.le L.A., Italy.

Comment

Jacques Galipeau et al. Cytotherapy. 2015 Feb.

. 2015 Feb;17(2):125-7.

doi: 10.1016/j.jcyt.2014.12.008.

¹ Department of Hematology and Medical Oncology, Winship Cancer Institute, and Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA. Electronic address: jgalipe@emory.edu.
² Section of Hematology, Stem Cell Research Laboratory and Cell Factory, Department of Medicine, University of Verona, Policlinico G.B. Rossi, P.le L.A., Italy.

No abstract available

Comment on

Standardization of Good Manufacturing Practice-compliant production of bone marrow-derived human mesenchymal stromal cells for immunotherapeutic applications.
Wuchter P, Bieback K, Schrezenmeier H, Bornhäuser M, Müller LP, Bönig H, Wagner W, Meisel R, Pavel P, Tonn T, Lang P, Müller I, Renner M, Malcherek G, Saffrich R, Buss EC, Horn P, Rojewski M, Schmitt A, Ho AD, Sanzenbacher R, Schmitt M. Wuchter P, et al. Cytotherapy. 2015 Feb;17(2):128-39. doi: 10.1016/j.jcyt.2014.04.002. Epub 2014 May 20. Cytotherapy. 2015. PMID: 24856898 Review.